Claris Lifesciences facility receives USFDA's positive nod

The US Food and Drug Administration (USFDA) has found the manufacturing facility of Claris Lifesciences, one of the leading manufacturers of sterile injectables in India, acceptable after an inspection. “The company has received a report from US FDA for the inspection it conducted classifying the finished dosage plant and the active pharma ingredients (API) plant as acceptable,” said Claris Lifesciences in a BSE filing.
 
The development is expected to give a boost to Claris Lifesciences as it will help it generate additional business in the regulated markets.
 
Claris Lifesciences has three manufacturing plants at its campus on the out skirts of Ahmedabad. The company manufactures and markets products across various therapeutic segments including anesthesia, blood products, anti-infective and renal care.